Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Polyplus-Transfection Launches Transfection Reagent for DNA and siRNA
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Polyplus-transfection has announced the launch of jetPRIME ™, a new reagent for DNA and siRNA transfection.
jetPRIME™ brings pharmaceutical and biotechnology researchers a number of advantages for day-to-day transfection experiments.
The reagent may be used for DNA as well as siRNA transfection in order to conduct transient gene expression studies and gene silencing by RNA interference. jetPRIME™ is efficient regardless of the nucleic acid delivered and gentle to cells because it uses smaller amounts of both nucleic acid and reagent compared to most reagents on the market. Furthermore, jetPRIME™ is adapted to co-transfection of DNA and siRNA.
"Today's announcement of jetPRIME™ brings a significant new extension to our range and demonstrates Polyplus-transfection's ability to develop powerful transfection reagents," said Frédéric Perraud, CEO of Polyplus-transfection. "It also shows our commitment to continually improve our core business - the development of innovative solutions for transfection and therapeutic nucleic acid delivery."
jetPRIME™ brings pharmaceutical and biotechnology researchers a number of advantages for day-to-day transfection experiments.
The reagent may be used for DNA as well as siRNA transfection in order to conduct transient gene expression studies and gene silencing by RNA interference. jetPRIME™ is efficient regardless of the nucleic acid delivered and gentle to cells because it uses smaller amounts of both nucleic acid and reagent compared to most reagents on the market. Furthermore, jetPRIME™ is adapted to co-transfection of DNA and siRNA.
"Today's announcement of jetPRIME™ brings a significant new extension to our range and demonstrates Polyplus-transfection's ability to develop powerful transfection reagents," said Frédéric Perraud, CEO of Polyplus-transfection. "It also shows our commitment to continually improve our core business - the development of innovative solutions for transfection and therapeutic nucleic acid delivery."
